Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment

Podobne knjige/članki

• STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
  od: Srivastava, Raghvendra M, et al.
  Izdano: (2013)
• T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response
  od: Kansy, Benjamin A., et al.
  Izdano: (2018)
• STAT1-Induced HLA class I Upregulation Enhances Immunogenicity and Clinical Response to anti-EGFR mAb Cetuximab Therapy in HNC Patients
  od: Srivastava, Raghvendra M., et al.
  Izdano: (2015)
• A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan
  od: Weiyi Qiu, et al.
  Izdano: (2019-01-01)
• A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan
  od: Qiu, Weiyi, et al.
  Izdano: (2019)